Inotiv, Inc. Announces Debt Financing and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc.

Rhea-AI Summary

Inotiv, Inc. (NASDAQ:NOTV) has completed the acquisition of HistoTox Labs for $22 million and merged with Bolder BioPATH, valued at $18.5 million plus shares and notes. These strategic moves aim to enhance Inotiv’s nonclinical pharmacology and histopathology services, expanding their capabilities in drug discovery and development. To support these acquisitions, Inotiv secured $28 million in debt financing from First Internet Bank. This expansion positions Inotiv to offer comprehensive laboratory solutions for preclinical drug safety and efficacy programs.

Positive

• Acquisition of HistoTox Labs enhances pharmacology and histopathology services.
• Merger with Bolder BioPATH increases market reach and service offerings.
• Secured $28 million in debt financing to support acquisitions.
• Strategic expansion to support clients in innovative drug therapies.

Negative

• Total cash outlay for acquisitions amounts to $40.5 million, which may impact liquidity.
• Integration challenges may arise from merging operations with Bolder BioPATH and HistoTox Labs.

WEST LAFAYETTE, Ind., April 30, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company has secured $28.0 million in debt financing from First Internet Bank of Indiana and completed the previously-announced acquisition of substantially all of the assets of HistoTox Labs, Inc. (“HistoTox Labs”) and the acquisition by merger of Bolder BioPATH, Inc. (“Bolder BioPATH”), effective April 30, 2021.

The aggregate consideration paid for substantially all of the assets of HistoTox Labs consisted of $22.0 million in cash and the assumption of certain specified liabilities of the seller.

The aggregate consideration paid to the shareholders of Bolder BioPATH in the merger consisted of $18.5 million in cash, 1,588,235 Inotiv common shares, and $1.5 million in subordinated notes.  

“These strategic acquisitions expand our nonclinical pharmacology and histopathology services and augment and extend the effective range of our services from early discovery through preclinical development,” said Robert Leasure, Jr., Inotiv’s President and Chief Executive Officer. “This will increase the breadth of discovery pharmacology models that we can offer clients pursuing traditional oral small molecule therapies to next generation injectables and gene therapies. By combining these acquisitions with our planned expansion and investments, we are positioned to offer comprehensive laboratory solutions in DMPK and cell & molecular biology, immunohistochemistry, and histopathology to clients pursuing preclinical drug safety and efficacy programs.”

A Current Report on Form 8-K containing further details regarding the debt financing will be filed by Inotiv and made available on the U.S. Securities and Exchange Commission’s EDGAR website.

About the Company

Inotiv, Inc. is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. The Company’s products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit inotivco.com for more information about the Company.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact	Investor Relations
Inotiv, Inc.	The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer	Kalle Ahl, CFA
(765) 497-8381	(212) 836-9614
btaylor@inotivco.com	kahl@equityny.com
	Devin Sullivan
	(212) 836-9608
	dsullivan@equityny.com

FAQ

What is the financial outcome of Inotiv's acquisitions on April 30, 2021?

Inotiv paid $22 million for HistoTox Labs and $18.5 million in cash plus shares for Bolder BioPATH.

How does the acquisition of HistoTox Labs affect Inotiv's services?

The acquisition will enhance Inotiv's pharmacology and histopathology service offerings, extending their capabilities.

What are the potential risks associated with Inotiv's merger with Bolder BioPATH?

Integration challenges may pose risks to operational efficiency and financial stability.

When did Inotiv complete the acquisition of HistoTox Labs and Bolder BioPATH?

The acquisitions were completed on April 30, 2021.

What is the purpose of Inotiv securing $28 million in debt financing?

The financing supports the recent acquisitions and facilitates expansion in service offerings.